Then, cobimetinib (MEK inhibitor), trametinib (MEK inhibitor), and dabrafenib (BRAF inhibitor) was approved by FDA to treat melanoma with BRAFV600 mutations, and trametinib and dabrafenib could also treat NSCLC with BRAFV600E mutation. Here, MAP2K7 is linked to non-small cell lung carcinoma.